Advances in Breast Cancer Treatment – three major trials

Recent advances in breast cancer research have shown practice changing findings. This review article wants to highlight key insights from three major breast cancer trials presented at the last 2024 ESMO congress: the HypoG-01 trial, which evaluated hypofractionated radiotherapy in localized breast cancer requiring nodal irradiation, the KEYNOTE-522 trial, which investigated the addition of pembrolizumab to chemotherapy in localized node positive triple-negative breast cancer (TNBC), and the NATALEE trial, which assessed adjuvant ribociclib in hormone receptor-positive high risk early breast cancer. These studies contribute to ongoing developments in personalized treatment strategies across various breast cancer subtypes.